Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus BILTRICIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus BILTRICIDE.
ALBENZA vs BILTRICIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Anthelmintic
Anthelmintic